Risk of Second Primary Malignancy in XXXX : A Nested Population-Based Case-Control Study.

@entity1 @entity0 @entity5345 @entity5 @entity2674 @entity259 @entity1722
PURPOSE: Evolving therapies have improved the prognoses of @entity1 with @entity0 ; and currently, the number of long-term survivors is continuously increasing. However, these @entity1 are at increased risk of developing a second @entity5 . Thus, late side effects are becoming an important issue. In this study, we aimed to investigate whether @entity1 and @entity5 characteristics, and treatment type correlate with secondary @entity5 risk. METHODS: This case-control study included 305 @entity1 with a diagnosed second @entity5 after almost 6 months after the diagnosis of primary @entity0 and 1,525 controls (ratio 1:5 of cases to controls) from a population-based cohort of 6,325 @entity1 . The control @entity1 were randomly selected from the cohort and matched to the cases according to age at diagnosis, calendar period of diagnosis, disease stage, and time of follow-up. RESULTS: @entity5345 or @entity2674 mutation, @entity1 @entity1722 ( @entity1722 )+ status, chemotherapy, and radiotherapy were related to increased risk of developing a second @entity5 , whereas hormonotherapy showed a protective effect. Chemotherapy, radiotherapy, and estrogenic receptor level <10% increased the risk of @entity0 . @entity1722 + status increased the risk of digestive system and @entity259 , while @entity5345 or @entity2674 mutation increased the risk of @entity5 in the genital system. CONCLUSION: @entity0 survivors are exposed to an excess of risk of developing a second @entity5 . The development of excess of @entity5 may be related either to @entity1 and @entity5 characteristics, such as @entity5345 or @entity2674 mutation and @entity1722 + status, or to treatments factors.
